← Browse by Condition
Medical Condition

unresectable hepatocellular carcinoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 3, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for unresectable hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — unresectable hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for unresectable hepatocellular carcinoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for unresectable hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for unresectable hepatocellular carcinoma?
unresectable hepatocellular carcinoma research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a unresectable hepatocellular carcinoma clinical trial?
Eligibility criteria for unresectable hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
1
Top Sponsors
Sun Yat-sen University 1 trial
Guohui Xu 1 trial
Academic and Community Cancer Research United 1 trial
Pfizer 1 trial

Recruiting Clinical Trials

NCT06788353
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
Enrollment
500 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06485466 Phase 3
Recruiting
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Enrollment
101 pts
Location
China
Sponsor
Guohui Xu
View Trial →
NCT05168163 Phase 2
Recruiting
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Enrollment
122 pts
Location
United States
Sponsor
Academic and Community Cancer ...
View Trial →
NCT07227012 Phase 1, Phase 2
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Enrollment
138 pts
Location
United States, Japan...
Sponsor
Pfizer
View Trial →

Related Conditions

transarterial chemoembolization (2) metastatic hepatocellular carcinoma (2) systemic therapy (1) camrelizumab (1) apatinib (1) locally advanced hepatocellular carcinoma (1) stage iii hepatocellular carcinoma ajcc v8 (1) stage iiia hepatocellular carcinoma ajcc v8 (1) stage iiib hepatocellular carcinoma ajcc v8 (1) stage iv hepatocellular carcinoma ajcc v8 (1) stage iva hepatocellular carcinoma ajcc v8 (1) stage ivb hepatocellular carcinoma ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology